CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 6,786	$ 8,612
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	53,422	50,319
Provision for bad debts	0	35,187
Equity in earnings of joint ventures	(9,547)	(8,372)
Distributions from joint ventures	21,783	6,785
Amortization of deferred financing costs and loan discount	2,924	2,509
(Gain) loss on sale and disposal of equipment	(2,204)	828
Gain on sale of imaging centers	0	(3,146)
Stock-based compensation	6,557	5,842
Non cash severance	0	1,047
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable	(9,641)	(38,770)
Other current assets	(5,680)	2,981
Other assets	(1,209)	309
Deferred taxes	1,531	2,031
Deferred rent	2,397	2,137
Deferred revenue	353	428
Accounts payable, accrued expenses and other	20,386	6,857
Net cash provided by operating activities	87,858	75,584
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities	(17,393)	(22,904)
Equity investments at fair value	(2,200)	(500)
Purchase of property and equipment	(62,595)	(52,807)
Proceeds from sale of equipment	2,587	571
Proceeds from sale of imaging and medical practice assets	0	8,429
Cash distribution from new JV partner	0	1,473
Equity contributions in existing and purchase of interest in joint ventures	(2,000)	(80)
Net cash used in investing activities	(81,601)	(65,818)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable	(4,374)	(5,297)
Proceeds from borrowings	0	170,000
Payments on Term Loan Debt	(24,810)	(188,396)
Distributions paid to noncontrolling interests	(913)	(1,065)
Deferred financing costs and debt discount	0	(5,067)
Proceeds from sale of noncontrolling interest, net of taxes	0	7,726
Contributions from noncontrolling partners	0	125
Purchase of non-controlling interests	(200)	0
Proceeds from revolving credit facility	44,000	139,400
Payments on revolving credit facility	(44,000)	(139,400)
Proceeds from issuance of common stock upon exercise of options	10	0
Net cash used in financing activities	(30,287)	(21,974)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(65)	38
NET DECREASE IN CASH AND CASH EQUIVALENTS	(24,095)	(12,170)
CASH AND CASH EQUIVALENTS, beginning of period	51,322	20,638
CASH AND CASH EQUIVALENTS, end of period	27,227	8,468
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest	27,136	29,134
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Equipment and leasehold improvements not yet paid for	14,200	14,400
Capital lease debt incurred	4,000	5,400
Investment in joint venture, capital contribution	750	3,000
Fixed assets received	15,000	0
Special distribution from controlled subsidiary adjustment to noncontrolling interest	9,200	0
Special distribution from controlled subsidiary additional paid in capital	$ 2,900	$ 0